Global /Taiwan /Healthcare /Drug Manufacturers - General /6827

MegaPro Biomedical Co., Ltd.

6827

• TPEX: 6827 • Delayed

12.75TWD -1.2%

0.4030 USD

As of 20 June 2026, MegaPro Biomedical Co., Ltd. has a market cap of $26.2M USD, ranking #35204 globally and #2157 in Taiwan. It ranks #3183 in the Healthcare sector, and #1075 in the Drug Manufacturers - General industry.

Global Rank

35204

Country Rank

2157

Sector Rank

3183

Industry Rank

1075

Key Stats

Market Cap

$26.2MUSD

828.43M TWD

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jassy Wang open_in_new

Founded

2014

Website

megaprobio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.2%	3.7%	25%	4.1%	-25%	2%	36%	-49%	-67%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6827 巨生生醫股份有限公司 ISIN: TW0006827009 Shares Out.: Shares Outstanding: 79.33M¹ TV: TradingView: TPEX: 6827 SA: Stock Analysis: TPEX: 6827 YF: Yahoo Finance: 6827.TWO GF: Google Finance: TPEX: 6827 BA: Barron's: 6827 MS: Morningstar: ROCO: 6827	12.75 TWD	TV: TradingView: TPEX: 6827 SA: Stock Analysis: TPEX: 6827 YF: Yahoo Finance: 6827.TWO GF: Google Finance: TPEX: 6827 BA: Barron's: 6827 MS: Morningstar: ROCO: 6827

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About MegaPro Biomedical Co., Ltd.

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.76B 245.34B TWD 30K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.83B 57.95B TWD 7K%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$920.72M 29.11B TWD 3K%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$805.08M 25.46B TWD 3K%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$785.01M 24.82B TWD 3K%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$581.1M 18.38B TWD 2K%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 2M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 1M%	97.4	United States
Roche Holding AG SIX: RO	$318.3B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.64B 215.59B GBP 1M%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 1M%	15.1	United States

chevron_leftBack